Date(s) - November 30, 2017
12:00 PM - 1:00 PM
On Thursday, November 30th from 12:00 to 1:00 pm Eastern Time, The Life Raft Group in collaboration with Blueprint Medicines will host an informational webcast for the GIST patient community about BLU-285, an investigational medicine for people with advanced GIST.
During the webcast, Dr. Andy Boral, Chief Medical Officer of Blueprint Medicines, will share an update on the BLU-285 program, including a summary of updated clinical trial results recently presented at The Connective Tissue Oncology Society 2017 Annual Meeting on November 10. Dr. Boral will also provide an update on ongoing and planned BLU-285 clinical trials.
We invite patients with GIST and their families to participate, and to submit questions in advance for the Q&A portion of the webcast. Questions may be submitted to Blueprint Medicines at email@example.com or to The Life Raft Group at firstname.lastname@example.org by Tuesday, November 28.
Following the event, a replay of the webcast will be made available in the “Patients” section of the Blueprint Medicines website under “Patient Community Events” located at: http://www.blueprintmedicines.com/patients/patient-community-events.
Thursday, November 30th
12:00 – 1:00 p.m., Eastern Time
Please connect several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
To Access Audio-Only:
Dial (877) 369-0926 (toll-free) or (646) 876-9923
The webinar ID is 293 916 752
International Numbers Available Here
About The Life Raft Group
The Life Raft Group is a non-profit with a simple focus: to cure a form of cancer – GIST (gastrointestinal stromal tumors) – and to help those living with it until then. The mission is to ensure the survival of GIST patients through a comprehensive approach connecting individual patients’ needs, the worldwide community of GIST advocates and the global health and research environment. This is achieved by focusing on three key areas: Patient Support & Education, Advocacy and Research.
To learn more, visit www.liferaftgroup.org
About Blueprint Medicines
Blueprint Medicines is developing a new generation of targeted kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development.
For more information, please visit www.blueprintmedicines.com